SEEBRI Drug Patent Profile
✉ Email this page to a colleague
When do Seebri patents expire, and when can generic versions of Seebri launch?
Seebri is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug.
The generic ingredient in SEEBRI is glycopyrrolate. There are seventeen drug master file entries for this compound. Sixty-two suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Seebri
A generic version of SEEBRI was approved as glycopyrrolate by AM REGENT on July 23rd, 1986.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for SEEBRI?
- What are the global sales for SEEBRI?
- What is Average Wholesale Price for SEEBRI?
Summary for SEEBRI
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for SEEBRI |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SEEBRI |
| DailyMed Link: | SEEBRI at DailyMed |
Recent Clinical Trials for SEEBRI
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Fundacio Privada Mon Clinic Barcelona | PHASE4 |
| GlaxoSmithKline | PHASE4 |
| University of Saskatchewan | Phase 4 |
US Patents and Regulatory Information for SEEBRI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | SEEBRI NEOHALER | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | DISCN | Yes | No | 8,479,730 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Novartis | SEEBRI NEOHALER | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | DISCN | Yes | No | 8,182,838 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
